Anlotinib　is　an　oral　tyrosine　kinase　inhibitor　targeting　vascular　endothelial　growth　factor　receptor,　fibroblast　growth　factor　receptor,　platelet-derived　growth　factor　receptor,　and　stem　cell　factor　receptor　(c-Kit).　In　the　phase　III　ALTER-0303　trial　(Clinical　Trial　Registry　ID:　NCT　02388919),　anlotinib　significantly　improved　overall　survival　versus　placebo　in　advanced　non-small　cell　lung　cancer　patients　who　had　received　at　least　two　previous　chemotherapy　and　epidermal　growth　factor　receptor/anaplastic　lymphoma　kinase　targeted　therapy　regimens.　This　study　summarized　adverse　event　management　in　this　trial.Patients　were　randomized　(2:1)　to　anlotinib　or　placebo　up　to　progression　or　intolerable　toxicity.　Adverse　events　were　graded　according　to　the　National　Cancer　Institute　Common　Terminology　Criteria　for　Adverse　Events　Version　4.0　and　managed　by　investigators.　Key　strategies　for　preventing　and　managing　the　most　common　adverse　events　included　patient　education,　supportive　care,　and　dose　modification.Between　February　2015　and　August　2016,　294　patients　received　anlotinib.　A　total　of　170　(57.8%)　patients　received　antihypertensive　medications　for　hypertension,　53　(18.0%)　patients　received　levothyroxine　for　hypothyroidism,　24　(8.2%)　patients　received　fibrates　for　hypertriglyceridemia,　11　(3.7%)　patients　took　cortisone　cream　for　hand-foot　syndrome,　and　38　(12.9%)　patients　received　anti-diarrheal　medications　for　diarrhea.　Dose　reduction　and　drug　discontinuation　were　required　in　24　(8.16%)　and　31　(10.54%)　patients　in　the　anlotinib　group,　respectively.Anlotinb-related　adverse　events　could　be　controlled　by　patient　education,　prophylactic　measures,　early　and　active　intervention,　and　dose　modification.